Top

Published in:

01-11-2020 | Neuroblastoma | Original Article

High-dose ¹³¹I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience

Authors: Hiroshi Wakabayashi, Daiki Kayano, Anri Inaki, Raita Araki, Rie Kuroda, Yasuhiro Ikawa, Toshihiro Fujiki, Norihito Akatani, Takafumi Yamase, Satoru Watanabe, Tomo Hiromasa, Yuji Kunita, Hiroshi Mori, Shintaro Saito, Ryosei Nishimura, Taizo Wada, Seigo Kinuya

Published in: Annals of Nuclear Medicine | Issue 11/2020

Abstract

Objective

Children with relapsed neuroblastoma have a poor prognosis despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for relapsed neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose ¹³¹I-meta-iodo-benzyl-guanidine (¹³¹I-mIBG) in relapsed neuroblastoma or ganglioneuroblastoma patients with complete response (CR) to induction therapy as demonstrated by diagnostic ¹²³I-mIBG scintigraphy.

Methods

Between December 2009 and 2014, five patients with relapsed neuroblastoma and one with relapsed ganglioneuroblastoma received high-dose ¹³¹I-mIBG therapy. Overall and progression-free survival rates at five years after ¹³¹I-mIBG therapy were analyzed by the Kaplan–Meier method.

Results

During follow-up, three children showed no signs of disease relapse, whereas three died. One child without a relapse died from post-transplant side effects, and two children with a relapse died owing to tumor progression. The 5-year progression-free and overall survival rates after ¹³¹I-mIBG therapy were 44% and 67%, respectively.

Conclusions

Consolidation therapy with high-dose ¹³¹I-mIBG for patients with 2^nd CR showed good overall and progression-free survival. While the risks of radiation exposure must be considered, high-dose ¹³¹I-mIBG therapy as consolidation therapy needs to be further investigated.

Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298–303. https://doi.org/10.1200/JCO.2008.16.6876.CrossRefPubMedPubMedCentral

Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992. Eur J Cancer. 2000;36:901–8.CrossRef

London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29:3286–92. https://doi.org/10.1200/JCO.2010.34.3392.CrossRefPubMedPubMedCentral

Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, et al. Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017;10:108. https://doi.org/10.1186/s13045-017-0477-0.CrossRefPubMedPubMedCentral

Suh JK, Koh KN, Min SY, Kim YS, Kim H, Im HJ, et al. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with (131) I-MIBG therapy for high-risk neuroblastoma. Pediatr Transplant. 2020;24:e13658. https://doi.org/10.1111/petr.13658.CrossRefPubMed

Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, et al. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2011;57:1124–9. https://doi.org/10.1002/pbc.23062.CrossRefPubMed

Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jurgens H, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer. 1998;34:1398–402. https://doi.org/10.1016/s0959-8049(98)00130-0.CrossRefPubMed

Ting G, Chang CH, Wang HE. Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res. 2009;29:4107–18.PubMed

Sgouros G. Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. J Nucl Med. 1995;36:1910–2.PubMed

10.

Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35:1039–47. https://doi.org/10.1007/s00259-008-0715-3.CrossRefPubMed

11.

Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50:1518–24. https://doi.org/10.2967/jnumed.109.064469.CrossRefPubMed

12.

Sung KW, Park JE, Chueh HW, Lee SH, Yoo KH, Koo HH, et al. Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr Blood Cancer. 2011;57:660–5. https://doi.org/10.1002/pbc.23035.CrossRefPubMed

13.

Yi ES, Son MH, Hyun JK, Cho HW, Ju HY, Lee JW, et al. Predictors of survival in patients with high-risk neuroblastoma who failed tandem high-dose chemotherapy and autologous stem cell transplantation. Pediatr Blood Cancer. 2020;67:e28066. https://doi.org/10.1002/pbc.28066.CrossRefPubMed

14.

Hickeson MP, Charron M, Maris JM, Brophy P, Kang TI, Zhuang H, et al. Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer. 2004;42:268–74. https://doi.org/10.1002/pbc.10454.CrossRefPubMed

15.

Yang J, Codreanu I, Servaes S, Zhuang H. I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma. Nucl Med Commun. 2012;33:1134–7. https://doi.org/10.1097/MNM.0b013e3283570ffe.CrossRefPubMed

16.

Pandit-Taskar N, Zanzonico P, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S. Assessment of organ dosimetry for planning repeat treatments of high-dose 131I-MIBG therapy: 123I-MIBG versus post therapy 131I-MIBG imaging. Clin Nucl Med. 2017;42:741–8. https://doi.org/10.1097/RLU.0000000000001752.CrossRefPubMedPubMedCentral

17.

Herd F, Basta NO, McNally RJQ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Eur J Cancer. 2019;111:50–8. https://doi.org/10.1016/j.ejca.2018.12.032.CrossRefPubMedPubMedCentral

18.

Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, et al. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016;66:144–52. https://doi.org/10.1016/j.ejca.2016.07.017.CrossRefPubMedPubMedCentral

Title: High-dose 131I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience
Authors: Hiroshi Wakabayashi
Daiki Kayano
Anri Inaki
Raita Araki
Rie Kuroda
Yasuhiro Ikawa
Toshihiro Fujiki
Norihito Akatani
Takafumi Yamase
Satoru Watanabe
Tomo Hiromasa
Yuji Kunita
Hiroshi Mori
Shintaro Saito
Ryosei Nishimura
Taizo Wada
Seigo Kinuya
Publication date: 01-11-2020
Publisher: Springer Singapore
Keywords: Neuroblastoma
Neuroblastoma
Scintigraphy
Published in: Annals of Nuclear Medicine / Issue 11/2020
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-020-01514-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

High-dose ¹³¹I-mIBG as consolidation therapy in pediatric patients with relapsed neuroblastoma and ganglioneuroblastoma: the Japanese experience

Abstract

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2020

Sentinel node biopsy in midline tumors: we should be careful and accurate

The 2020 national diagnostic reference levels for nuclear medicine in Japan

Deceased vs. living donor kidney transplantation in prediction of acute renal allograft rejection using Tc-99m DTPA renal scan

Standardization of PET imaging and site qualification program by JSNM: collaboration with EANM/EARL

Development of 68Ga-labeled tin colloids for evaluating phagocytic function of Kupffer cells using preclinical PET imaging

Discontinuation of metformin to prevent metformin-induced high colonic FDG uptake: is 48 h sufficient?